SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-024238
Filing Date
2022-05-05
Accepted
2022-05-05 16:31:57
Documents
61
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_protaratherap.htm   iXBRL 10-Q 868545
2 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY f10q0322ex10-1_protara.htm EX-10.1 14541
3 EXECUTIVE EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 10, 2022, BY AND BETWEEN f10q0322ex10-2_protara.htm EX-10.2 60794
4 CERTIFICATION f10q0322ex31-1_protara.htm EX-31.1 13445
5 CERTIFICATION f10q0322ex31-2_protara.htm EX-31.2 13080
6 CERTIFICATION f10q0322ex32-1_protara.htm EX-32.1 8093
  Complete submission text file 0001213900-22-024238.txt   3926206

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tara-20220331.xsd EX-101.SCH 47568
8 XBRL CALCULATION FILE tara-20220331_cal.xml EX-101.CAL 22290
9 XBRL DEFINITION FILE tara-20220331_def.xml EX-101.DEF 182683
10 XBRL LABEL FILE tara-20220331_lab.xml EX-101.LAB 372540
11 XBRL PRESENTATION FILE tara-20220331_pre.xml EX-101.PRE 195050
55 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_protaratherap_htm.xml XML 351062
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 22896914
SIC: 2836 Biological Products, (No Diagnostic Substances)